| RA-CAPITAL-MANAGEMENT-L-P |
RA-CAPITAL-MANAGEMENT-L-P |
92%
|
the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of … |
| CABA |
Cabaletta Bio, Inc. |
72%
|
Reciprocal relationship from CABA graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate… |
| CABA |
Cabaletta Bio, Inc. |
72%
|
ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r… |
| CGEM |
Cullinan Therapeutics, Inc. |
72%
|
ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r… |
| CGEM |
Cullinan Therapeutics, Inc. |
72%
|
Reciprocal relationship from CGEM graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate… |
| JBIO |
Jade Biosciences, Inc. |
72%
|
ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r… |
| JBIO |
Jade Biosciences, Inc. |
72%
|
Reciprocal relationship from JBIO graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from JBIO g… |
| KYTX |
Kyverna Therapeutics, Inc. |
72%
|
Reciprocal relationship from KYTX graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical stud… |
| KYTX |
Kyverna Therapeutics, Inc. |
72%
|
ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipat… |
| VERA |
Vera Therapeutics, Inc. |
72%
|
Reciprocal relationship from VERA graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate… |
| VERA |
Vera Therapeutics, Inc. |
72%
|
ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
Reciprocal relationship from VRTX graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from VRTX g… |
| ZBIO |
Zenas BioPharma, Inc. |
72%
|
Reciprocal relationship from ZBIO graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical stud… |
| ZBIO |
Zenas BioPharma, Inc. |
72%
|
ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r… |
| CANCER-RESEARCH-TECHNOLOGY-LIMITED |
CANCER-RESEARCH-TECHNOLOGY-LIMITED |
62%
|
ly affected. • We face significant competition in an environment of rapid technological change, and our competitors may develop or obtain regulatory approval for products before us or develop product… |
| CLMB |
Climb Global Solutions, Inc. |
62%
|
Reciprocal relationship from CLMB graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from CLMB graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from CLMB g… |
| PRESENTATION-ORGANIZATION-CLIMB-BIO-INC |
PRESENTATION-ORGANIZATION-CLIMB-BIO-INC |
62%
|
ions and Basis of Presentation Organization Climb Bio, Inc. (the Company), is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s … |
| PROBIOGEN-AG |
PROBIOGEN-AG |
62%
|
proved products in other markets; • obtain coverage and adequate reimbursement from third-party payors, including government and private payors; • achieve market acceptance for any products; • establ… |
| QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY |
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY |
62%
|
f regulatory requirements, regulatory submissions and timing of regulatory approvals; • the costs involved in prosecuting and enforcing patent and other intellectual property claims; • the potential … |
| TECHNOLOGY-LIMITED |
TECHNOLOGY-LIMITED |
62%
|
search Technology Limited (CRH). With respect to CLYM116, we have one exclusively in-licensed PCT application under the Mabworks Agreement and co-own three pending provisional patent applications wit… |
| TENET-MEDICINES-INC |
TENET-MEDICINES-INC |
62%
|
proved products in other markets; • obtain coverage and adequate reimbursement from third-party payors, including government and private payors; • achieve market acceptance for any products; • establ… |
